Last reviewed · How we verify
NCT05840042
Epidemiology and Risk Factors of Uterine Fibroids in China
trial in Uterine Fibroid in 20,000 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Shixuan Wang |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 20,000 |
| Start date | 19 June 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
Conditions studied
- Uterine Fibroid — all drugs for Uterine Fibroid →
Sponsor
Shixuan Wang
Who can join
18 and older, female only, with Uterine Fibroid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Uterine fibroids are the most common form of benign uterine tumors in the uterine muscle layer, which had a certain rate of malignancy, but it is rare. The prevalence of uterine fibroids estimates range from 4.5% to 68.6% depending on study population and diagnostic methodology. The prevalence of fibroids has been historically underestimated by epidemiologic studies which focused mainly on symptomatic women, leaving behind a large population of asymptomatic women and women who underreport their symptoms. What investigators don't know was which women who have fibroids will develop clinical symptoms and which women who have an operation of myomectomy will relapse. The purpose of this study is to investigate the prevalence, incidence and risk factors for the development of uterine fibroids in Chinese women.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Status and treatment of patients with uterine fibroids in hospitals in central China: a retrospective study from 2018 to 2021.
Yan W, Yuan S, Zhou D, Zhang M, et al · · 2024 · cited 2× · PMID 38233053 · DOI 10.1136/bmjopen-2023-081736
Verify or expand the search:
- PubMed search for NCT05840042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uterine Fibroid
Currently open trials in the same condition.
- NCT07173127 — The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemos · NA · recruiting
- NCT06705075 — Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE · Phase 2 · recruiting
- NCT06244251 — Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids · NA · active not recruiting
- NCT05386615 — Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids · recruiting
Other Shixuan Wang trials
Trials by the same sponsor.
- NCT05881967 — Molecular Mechanism Study of Uterine Sarcoma · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05840042 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shixuan Wang
- Last refreshed: 22 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05840042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing